74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Medtronic PLC
Open
Sector Healthcare
89.96 2.94
Overview
Share price change
24h
Min
87.23
Max
90.79
Income | 32M 1.3B |
|---|---|
Sales | -111M 8.3B |
P/E Sector Avg | 26.524 73.394 |
EPS | 1.39 |
Dividend yield | 3.22 |
Profit margin | 15.798 |
Employees | 95,000 |
EBITDA | -2.1B 372M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +9.93 upside |
Dividend yield Sector Avg | 3.22% 3.09% |
|---|---|
Next Dividend date | 11 Apr 2025 |
Next Ex Dividend date | 20 Mar 2025 |
Market Cap | -9B 112B |
|---|---|
Previous open | 87.02 |
Previous close | 89.96 |
News Sentiment
By Acuity
39%
61%
150 / 393 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Medtronic PLC Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Medtronic PLC Forecast
Price Target
By TipRanks
9.93% upside
12 Months Forecast
Average 95.64 USD 9.93%
High 109 USD
Low 85 USD
Based on 18 Wall Street analysts offering 12 month price targets forMedtronic PLC - Dist in the last 3 months.
Sentiment
By Acuity
150 / 393 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Above average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Medtronic PLC
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves, surgical valve replacement and repair products, endovascular stent grafts and accessories, and transcatheter pulmonary valves; and percutaneous coronary intervention products, percutaneous angioplasty balloons, and other products. The Neuroscience Portfolio segment offers medical devices and implants, biologic solutions, spinal cord stimulation and brain modulation systems, implantable drug infusion systems, and interventional products, as well as nerve ablation system under the Accurian name. The segment offers its products for spinal surgeons, neurosurgeons, neurologists, pain management specialists, anesthesiologists, orthopedic surgeons, urologists, urogynecologists, and interventional radiologists, as well as ear, nose, and throat specialists; and energy surgical instruments. The Medical Surgical Portfolio segment offers surgical stapling devices, vessel sealing instruments, wound closure and electrosurgery products, AI-powered surgical video and analytics platform, robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology products, gastrointestinal and hepatologic diagnostics and therapies, and therapies to treat other non-exclusive diseases and conditions; and patient monitoring and airway management products. The Diabetes Operating Unit segment provides insulin pumps and consumables, continuous glucose monitoring systems, and InPen, a smart insulin pen system. The company was founded in 1949 and is headquartered in Galway, Ireland.
